Comparative analysis of RNA-Seq data with DESeq2

Simon Anders EMBL Heidelberg



Two applications of RNA-Seq

Discovery

- find new transcripts
- find transcript boundaries
- find splice junctions

Comparison

Given samples from different experimental conditions, find effects of the treatment on

- gene expression strengths
- isoform abundance ratios, splice patterns, transcript boundaries

Sequencing count data


	control-1	control-2	control-3	treated-1	treated-2
FBgn0000008	78	46	43	47	89
FBgn000014	2	0	0	0	0
FBgn0000015	1	0	1	0	1
FBgn000017	3187	1672	1859	2445	4615
FBgn000018	369	150	176	288	383
[1					


- RNA-Seq
- Tag-Seq
- ChIP-Seq
- HiC
- Bar-Seq
- ...

Counting rules

- Count reads, not base-pairs
- Count each read at most once.
- Discard a read if
 - it cannot be uniquely mapped
 - its alignment overlaps with several genes
 - the alignment quality score is bad
 - (for paired-end reads) the mates do not map to the same gene


Why we discard non-unique alignments






 If sample A has been sampled deeper than sample B, we expect counts to be higher.

- Naive approach: Divide by the total number of reads per sample
- Problem: Genes that are strongly and differentially expressed may distort the ratio of total reads.



Histogram of log2(sample2/sample1)



To compare more than two samples:

- Form a "virtual reference sample" by taking, for each gene, the geometric mean of counts over all samples
- Normalize each sample to this reference, to get one scaling factor ("size factor") per sample.

Anders and Huber, 2010

similar approach: Robinson and Oshlack, 2010

Counting noise

In RNA-Seq, noise (and hence power) depends on count level.


Why?

The Poisson distribution



 This bag contains very many small balls, 10% of which are red.

 Several experimenters are tasked with determining the percentage of red balls.



 Each of them is permitted to draw 20 balls out of the bag, without looking.

$$3/20 = 15\%$$

$$7/100 = 7\%$$

$$10 / 100 = 10\%$$


$$8/100 = 8\%$$

Poisson distribution: Counting uncertainty


expected number of red balls	standard deviation of number of red balls	relative error in estimate for the fraction of red balls
10	$\sqrt{10} = 3$	1 / √10 = 31.6%
100	$\sqrt{100} = 10$	$1/\sqrt{100} = 10.0\%$
1,000	$\sqrt{1,000} = 32$	$1/\sqrt{1000} = 3.2\%$
10,000	$\sqrt{10,000} = 100$	$1/\sqrt{10000} = 1.0\%$

The negative binomial distribution

A commonly used generalization of the Poisson distribution with *two* parameters



The NB from a hierarchical model



Biological sample with mean μ and variance ν

Poisson distribution with mean *q* and variance *q*.

Negative binomial with mean μ and variance q+v.

Testing: Generalized linear models

Two sample groups: treatment and control.

Model:

- Count value K_{ij} for a gene in sample j is generated by NB distribution with mean $s_j \mu_j$ and dispersion α .
- The expected expression strength is:

$$\log \mu_j = \beta_{i0} + x_j \beta_{iT}$$

 $x_j = 0$ if j is control sample $x_j = 1$ if j is treatment sample

Null model:

 β_{iT} = 0, i.e., expectation is the same for all samples

Alternative model:

 $\beta_{iT} \neq 0$, i.e., expected expression changes from control to treatment, with log fold change (LFC) β_T

Testing: Generalized linear models

$$K_{ij} \sim \text{NB} (s_j \mu_{ij}, \alpha_i)$$

 $\log \mu_{ij} = \beta_{i0} + x_j \beta_{iT}$

 $x_j = 0$ for if j is control sample $x_j = 1$ for if j is treatment sample

Calculate the coefficients β that fit best the observed data K.

Is the value for β_{iT} significantly different from null?

Can we reject the null hypothesis that it is merely cause by noise (as given by the dispersion α_i)?

We use a Wald test to get a *p* value.

Tasks in comparative RNA-Seq analysis

Estimate fold-change between control and treatment

• Estimate variability within groups

the hard part

Determine significance

Dispersion


Minimum variance of count data:

$$v = \mu$$
 (Poisson)


Actual variance:

$$v = \mu + \alpha \mu^2$$


• α : "dispersion" $\alpha = (\mu - v) / \mu^2$ (squared coefficient of variation of extra-Poisson variability)




Shrinkage estimation of dispersion (within-group variability)



Shrinkage estimation of dispersion (within-group variability)




Shrinkage estimation of dispersion (within-group variability)





Shrinkage estimation of effect sizes

without shrinkage



with shrinkage





Complex designs

Simple: Comparison between two groups.

More complex:

- paired samples
- testing for interaction effects
- accounting for nuisance covariates
- . . .

GLMs: Blocking factor

Sample	treated	sex
S1	no	male
S2	no	male
S3	no	male
S4	no	female
S5	no	female
S6	yes	male
S7	yes	male
S8	yes	female
S9	yes	female
S10	yes	female

GLMs: Blocking factor

$$K_{ij} \sim NB(s_j \mu_{ij}, \alpha_{ij})$$

full model for gene *i*:

$$\log \mu_{ij} = \beta_i^0 + \beta_i^S x_j^S + \beta_i^T x_j^T$$

reduced model for gene *i*:

$$\log \mu_{ij} = \beta_i^0 + \beta_i^S x_i^S$$

GLMs: Interaction

$$K_{ij} \sim NB(s_j \mu_{ij}, \alpha_{ij})$$

full model for gene *i*:

$$\log \mu_{ij} = \beta_i^0 + \beta_i^S x_j^S + \beta_i^T x_j^T + \beta_i^I x_j^S x_j^T$$

reduced model for gene i:

$$\log \mu_{ij} = \beta_i^0 + \beta_i^S x_j^S + \beta_i^T x_j^T$$

GLMs: paired designs

- Often, samples are paired (e.g., a tumour and a healthy-tissue sample from the same patient)
- · Then, using pair identity as blocking factor improves power.

full model:

$$\log \mu_{ijl} = \beta_i^0 + \begin{cases} 0 & \text{for } l = 1(\text{healthy}) \\ \beta_i^{\text{T}} & \text{for } l = 2(\text{tumour}) \end{cases}$$

reduced model:

$$\log \mu_{ij} = \beta_i^0$$

$$j$$
 subject

l tissue state

GLMs: Dual-assay designs

How does the affinity of an RNA-binding protein to mRNA change under some drug treatment?

Prepare control and treated samples (in replicates) and perform on each sample RNA-Seq and CLIP-Seq.

For each sample, we are interested in the ratio of CLIP-Seq to RNA-Seq reads.

How is this ratio affected by treatment?

GLMs: CLIP-Seq/RNA-Seq assay

full model:

count ~ assayType + treatment + assayType:treatment

reduced model:

count ~ assayType + treatment

GLMs: CLIP-Seq/RNA-Seq assay

full model:

count ~ sample + assayType + assayType:treatment

reduced model:

count ~ sample + assayType

Genes and transcripts


So far, we looked at read counts per gene.

A gene's read count may increase


- because the gene produces more transcripts
- because the gene produces *longer* transcripts

How to look at gene sub-structure?

Assigning reads to transcripts



Assigning reads to transcripts



total: A: 55 reads

B: 165 reads (accuracy?)

One step back: Differential exon usage


Our tool, *DEXSeq*, tests for differential usage of exons.

Usage on an exon =


number of reads mapping to the exon

number of reads mapping to any other exon of the same gene


Differential exon usage -- Example



Differential exon usage -- Example



Differential usage of exons or of isoforms?



casette exon with well-understood function

casette exon with uncharacterized function

Summary

- Estimating fold-changes without estimating variability is pointless.
- Estimating variability from few samples requires information sharing across genes (shrinkage)
- Shrinkage can also regularize fold-change estimates. (New in DESeq2)

Acknowledgements

Co-authors:

- Wolfgang Huber
- Alejandro Reyes
- Mike Love (MPI-MG Berlin)

Thanks also to

- the rest of the Huber group
- all users who provided feed-back

Funding:









Fisher's exact test between two samples

Example data: fly cell culture, knock-down of pasilla (Brooks et al., Genome Res., 2011)

knock-down sample T2 versus control sample U3



control sample U2 versus control sample U3



red: significant genes according to Fisher test (at 10% FDR)